M Emmy M Dolman Selected Research

olaparib

9/2020

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Emmy M Dolman Research Topics

Disease

13	Neuroblastoma 01/2022 - 01/2014
12	Neoplasms (Cancer) 01/2022 - 01/2015
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2021 - 01/2021
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 05/2016
1	Osteosarcoma (Osteogenic Sarcoma) 01/2022
1	Medulloblastoma 01/2022
1	Glioma (Gliomas) 01/2022
1	Rhabdoid Tumor (Rhabdoid Tumors) 01/2021
1	Leukemia 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2020
1	Carcinogenesis 05/2016
1	Retinoblastoma (Glioblastoma, Retinal) 11/2015
1	Ischemia 07/2014
1	Hypoxia (Hypoxemia) 07/2014
1	Renal Insufficiency (Renal Failure) 07/2014
1	Tics (Tic) 02/2014
1	Inflammation (Inflammations) 11/2012

Drug/Important Bio-Agent (IBA)

6	Pharmaceutical PreparationsIBA 10/2021 - 03/2015
3	Proteins (Proteins, Gene)FDA Link 05/2016 - 02/2014
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2015
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2015
2	Apoptosis Regulatory ProteinsIBA 01/2021 - 05/2016
2	venetoclaxIBA 01/2021 - 05/2016
2	4- (2,6- dichlorobenzoylamino)- 1H- pyrazole- 3- carboxylic acid piperidin-4-ylamideIBA 11/2015 - 01/2014
1	pyrvinium (Vankin)FDA Link 05/2021
1	Tumor Suppressor Protein p14ARF (p14ARF)IBA 01/2021
1	Adenine FDA LinkGeneric 01/2021
1	Biological ProductsIBA 01/2021
1	Cyclin D1IBA 01/2021
1	RG7388IBA 01/2021
1	CytosineIBA 01/2021
1	Gemcitabine FDA Link 11/2020
1	RNA (Ribonucleic Acid)IBA 11/2020
1	Irinotecan (Camptosar)FDA LinkGeneric 09/2020
1	olaparibIBA 09/2020
1	GSK-2816126IBA 01/2017
1	Histone MethyltransferasesIBA 01/2017
1	Lysine (L-Lysine)FDA Link 01/2017
1	Polycomb Repressive Complex 2IBA 01/2017
1	MethyltransferasesIBA 01/2017
1	Histones (Histone)IBA 01/2017
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2015
1	Cyclin-Dependent Kinase 2IBA 11/2015
1	NucleophosminIBA 11/2015
1	dabrafenibIBA 03/2015
1	omipalisibIBA 03/2015
1	acetonitrileIBA 03/2015
1	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 01/2015
1	2-(morpholin-4-yl)benzo(h)chromen-4-oneIBA 01/2015
1	DNA-Activated Protein KinaseIBA 01/2015
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2015
1	AntioxidantsIBA 07/2014
1	Superoxides (Superoxide)IBA 07/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2014
1	8- (4- chloro- phenylthio)- 2'- O- methyladenosine- 3'- 5'- cyclic monophosphateIBA 07/2014
1	erythromycin propionate-N-acetylcysteinateIBA 07/2014
1	Cisplatin (Platino)FDA LinkGeneric 07/2014
1	Messenger RNA (mRNA)IBA 02/2014
1	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 02/2014
1	Serum-Free Culture MediaIBA 02/2014
1	rho-Associated KinasesIBA 11/2012

Therapy/Procedure

5	Therapeutics 01/2021 - 01/2015
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2015
1	Radiotherapy 01/2022
1	Precision Medicine 11/2020
1	Aftercare (After-Treatment) 11/2015
1	Combined Modality Therapy 11/2015
1	Oral Administration 03/2015
1	Kidney Transplantation 11/2012